Logo IFCT

Select your language

  • FR

MAPS

  • Publications:
  • A Defect of Amphiregulin Release Predicted Longer Survival Independently of YAP Expression in Patients with Pleural Mesothelioma in the IFCT-0701 MAPS Phase 3 Trial
  • Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial
  • Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
  • Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial.
  • Impact on health-related quality of life of the addition of bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS phase III trial
  • MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial
  • Post-Discontinuation Treatments in IFCTGFPC-0701 MAPS Trial: Real-World Effectiveness of 2nd-Line (2L) Treatments for Mesothelioma
  • Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort
  • VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial
  • Synopsis: Synopsis_MAPSv11.pdf

Intergroupe Francophone de Cancérologie Thoracique

Siège social
10 rue de la Grange-Batelière
75009 PARIS

Standard : 01.56.81.10.45
Recherche Clinique : 01.56.81.10.46
Permanence téléphonique du lundi au vendredi : 9h-13h / 14h-17h

Informations

  • Mentions légales
  • Avertissement

Suivez-nous

  • TwitterTwitter
  • LinkedIn
© IFCT 2025 - IFCT_TOUS_DROITS_RESERVES
Contact Devenir membre Espace membre E-lettre Deconnexion